Vimarsana.com

Latest Breaking News On - Shawn iadonato - Page 1 : vimarsana.com

Kineta (KA) to Explore Strategic Alternatives, Cuts Staff, Terminates CEO

Kineta (KA) to Explore Strategic Alternatives, Cuts Staff, Terminates CEO
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Pauline-kenny
Shawn-iadonato
Company-board-of-directors
Current-report
Chief-executive-officer
Iadonato-separation-agreement
Iadonato-consulting-agreement
Iadonato-consulting-period
Employment-agreement
Termination-without
General-counsel
Kenny-separation-agreement

Kineta (KA) Announces Restructuring and Exploration of Strategic Alternatives

Kineta (KA) Announces Restructuring and Exploration of Strategic Alternatives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shawn-iadonato
Pauline-kenny
Nasdaq
Kineta-inc
Chief-executive-officer
General-counsel

Kineta Announces Restructuring and Exploration of Strategic Alternatives

29.02.2024 - SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) - Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has ... Seite 1

Shawn-iadonato
Pauline-kenny
Nasdaq
Kineta-inc
Chief-executive-officer
General-counsel
Kineta-chart
Ineta-kurs
Ineta-aktie

Seattle biotech company Kineta lays off majority of staff, including its CEO

Seattle biotech company Kineta lays off majority of staff, including its CEO
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.

Shawn-iadonato
Yumanity-therapeutics

Kineta Shares Plunge on CEO Exit, Other Layoffs As It Explores Strategic Options

By Sabela Ojea Shares of Kineta on Thursday plunged after the company said it is letting go Chief Executive Shawn Iadonato as it mulls strategic options for...

Sabela-ojea
Shawn-iadonato
Chief-executive-shawn-iadonato

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Robert-burns
Shawn-iadonato
Thierry-guillaudeux
Bruce-macklelifesci-advisors
Jacques-bouchyevp-investor-relations-business-development
Linkedin
Nasdaq
Facebook
Kineta-inc
Home-fireside-chat-series
Chief-executive-officer
Chief-scientific-officer

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Shawn-iadonato
Thierry-guillaudeux
Bruce-macklelifesci-advisors
Linkedin
Merck-co-inc
Merck-sharp-dohme
Jacques-bouchyevp-investor-relations-business-development
Nasdaq
Facebook
Kineta-inc
Initial-combination-cohort

Kineta (KA) Provides Update on its Ongoing Phase 1/2 VISTA-101 Trial of KVA12123

Kineta (KA) Provides Update on its Ongoing Phase 1/2 VISTA-101 Trial of KVA12123
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Thierry-guillaudeux
Shawn-iadonato
Kineta-inc
Merck-co-inc
Nasdaq
Merck-sharp-dohme
Chief-executive-officer
Receptor-occupancy
Chief-scientific-officer
Merck-sharp

Kineta Issues Update On Phase 1/2 VISTA-101 Trial Of KVA12123 - Quick Facts

(RTTNews) - Kineta, Inc. (KA) issued an update on ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid t...

Shawn-iadonato
Kineta-inc
More-such-health-news

vimarsana © 2020. All Rights Reserved.